Royal Marsden NHS Foundation Trust
royalmarsden.nhs.ukTotal trials
267
Active
54
Phase 3
11
Total enrollment
10,075,987
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 29 of 29 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Capecitabine | — | — | — | — | — | 3 | |
| Nivolumab | — | — | — | — | — | 3 | |
| Single agent zimberelimab | — | — | — | — | — | 1 | |
| Combination zimberelimab + domvanalimab | — | — | — | — | — | 1 | |
| Palbociclib 125Mg Tab | — | — | — | — | — | 1 | |
| Fulvestrant | — | — | — | — | — | 1 | |
| Tamoxifen | — | — | — | — | — | 1 | |
| Letrozole | — | — | — | — | — | 1 | |
| Exemestane | — | — | — | — | — | 1 | |
| Anastrozole | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | — | 1 | |
| MEDI4736 | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 1 | |
| Rucaparib | — | — | — | — | — | 1 | |
| Ramucirumab | — | — | — | — | — | 1 | |
| Ipatasertib 300mg | — | — | — | — | — | 1 | |
| Fulvestrant 500g | — | — | — | — | — | 1 | |
| Palbociclib 75mg-125mg | — | — | — | — | — | 1 | |
| CDK4/6 Inhibitor | — | — | — | — | — | 1 | |
| 68Ga-PSMA | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | 11 | ||
| Avelumab | — | — | — | 3 | |||
| Palbociclib | — | — | — | — | — | 1 | |
| Guadecitabine | — | — | — | — | — | 1 | |
| ASTX727 | — | — | — | — | — | 1 | |
| Circulating tumour DNA dynamics | — | — | — | — | — | 1 | |
| Molecular Analyses | — | — | — | — | — | 1 | |
| DNA sequencing, RNA gene expression analysis, molecular profiling | — | — | — | — | — | 1 | |
| Molecular Analysis | — | — | — | — | — | 1 |
Next readouts
- 2022-10-21
- 2025-01-15
- 2025-03-30
- 2025-04-17
- 2025-12-31
- 2026-04
- 2026-07-31
- 2026-09
- 2027-03-20
- 2027-06
Top conditions
- Breast Cancer33
- Cancer17
- Prostate Cancer16
- Head and Neck Cancer14
- Lung Cancer9
- Ovarian Cancer9
- Colorectal Cancer9
- Gastric Cancer8
Frequently asked questions about Royal Marsden NHS Foundation Trust
- How many clinical trials does Royal Marsden NHS Foundation Trust have on ClinicalTrials.gov?
- Royal Marsden NHS Foundation Trust is listed as the lead sponsor on 267 clinical trials in ClinicalTrials.gov, 54 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Royal Marsden NHS Foundation Trust's trials are in Phase 3?
- 11 of Royal Marsden NHS Foundation Trust's trials are in Phase 3, spread across 29 active drug programs.
- What therapeutic areas does Royal Marsden NHS Foundation Trust focus on?
- Royal Marsden NHS Foundation Trust's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Prostate Cancer, Head and Neck Cancer, Lung Cancer.
- When are Royal Marsden NHS Foundation Trust's next clinical trial readouts?
- Royal Marsden NHS Foundation Trust has 10 upcoming primary-completion readouts tracked here; the soonest is “iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer”, expected around 2022-10-21.